Molecular Templates Inc MTEM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MTEM is a good fit for your portfolio.
News
-
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
-
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
-
Molecular Templates to Participate in Upcoming Investor Conferences
-
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
Trading Information
- Previous Close Price
- $4.88
- Day Range
- $4.93–5.00
- 52-Week Range
- $4.65–9.56
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $26.87 Mil
- Volume/Avg
- 6,366 / 8,209
Key Statistics
- Price/Earnings (Normalized)
- 6.70
- Price/Sales
- 0.42
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 222
- Website
- https://www.mtem.com
Competitors
Valuation
|
Metric
|
MTEM
|
RHHBY
|
LLY
|
|---|---|---|---|
Price/Earnings (Normalized) | 6.70 | 13.59 | 73.30 |
Price/Book Value | 3.91 | 7.68 | 49.55 |
Price/Sales | 0.42 | 3.48 | 16.50 |
Price/Cash Flow | — | 11.72 | 77.25 |
Price/Earnings
MTEM
RHHBY
LLY
Financial Strength
|
Metric
|
MTEM
|
RHHBY
|
LLY
|
|---|---|---|---|
Quick Ratio | 0.73 | 0.72 | 0.58 |
Current Ratio | 1.06 | 1.18 | 1.05 |
Interest Coverage | −5.86 | 17.42 | 14.87 |
Quick Ratio
MTEM
RHHBY
LLY
Profitability
|
Metric
|
MTEM
|
RHHBY
|
LLY
|
|---|---|---|---|
Return on Assets (Normalized) | −29.25% | 17.37% | 10.19% |
Return on Equity (Normalized) | — | 56.49% | 49.42% |
Return on Invested Capital (Normalized) | −61.06% | 27.41% | 19.29% |
Return on Assets
MTEM
RHHBY
LLY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tqgk | $454.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qwtgp | $90.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tfbsc | $89.7 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Zzbdpcc | $40.2 Bil | |
MRNA
| Moderna Inc | Dmch | $30.5 Bil | |
ARGX
| argenx SE ADR | Xvrf | $27.0 Bil | |
BNTX
| BioNTech SE ADR | Pqtn | $23.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mhqgbf | $21.7 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xkjrzn | $17.8 Bil | |
INCY
| Incyte Corp | Kgvytl | $12.3 Bil |